碳离子放疗治疗局部晚期胰腺癌:单臂研究系统综述与汇总分析
该系统综述汇总9项单臂研究共406例局部晚期胰腺癌患者,评估碳离子放疗(CIRT)的疗效与安全性。汇总1年、2年局部控制率分别为84%和64%,1年、2年总生存率分别为65%和38%;高剂量、同步化疗及既往化疗与更优疗效相关,≥G3非血液学与血液学毒性发生率分别为8%和24%。
要点
- 汇总1年、2年局部控制率84%和64%,1年、2年总生存率65%和38%。
- 高处方剂量者局部控制更优(1年89%对69%,2年72%对30%)。
- 同步化疗者生存优于未同步者,≥G3非血液学毒性8%。
核心结论
- CIRT治疗局部晚期胰腺癌显示出令人鼓舞的局部控制和总生存结果,是可行的治疗策略。
- 亚组分析提示更高剂量、同步化疗和既往化疗可能进一步增强疗效。
- 即使与化疗同步进行,CIRT的毒性仍可接受。
研究设计与样本
- 系统检索Embase、PubMed和Cochrane Library数据库至2025年9月的研究。
- 纳入CIRT治疗局部晚期胰腺癌的前瞻性或回顾性临床研究,允许联合化疗。
- 由2名研究者独立筛选文献并提取数据,采用STATA 15.1进行统计分析。
- 共检索到522篇相关文章,最终纳入9项单臂研究、406例患者。
主要发现
- 汇总1年和2年局部控制率分别为84%和64%。
- 高处方剂量组局部控制优于低剂量组(1年89%对69%,2年72%对30%)。
- 1年和2年总生存率分别为65%和38%。
- 同步化疗研究较未同步化疗研究生存更优(1年73%对53%,2年44%对22%)。
- 既往化疗使远处转移发生率降低(69%对85%)。
关键数值与推荐
- ≥G3非血液学毒性汇总发生率为8%,血液学毒性为24%。
- 1年局部控制率84%,2年局部控制率64%。
- 1年总生存率65%,2年总生存率38%。
- 高剂量组1年局部控制率89%、2年72%;低剂量组1年69%、2年30%。
- 同步化疗组1年总生存率73%、2年44%;无同步化疗组1年53%、2年22%。
临床怎么用
- 对局部晚期胰腺癌可考虑CIRT作为治疗选择,尤其适合无法手术且需局部控制者。
- 在安全前提下采用较高处方剂量,并考虑同步化疗以改善生存。
- 既往化疗可能降低远处转移风险,可纳入综合治疗策略考量。
- 治疗中需关注血液学毒性,≥G3血液学毒性汇总发生率为24%。
局限性
- 证据仅来自单臂研究,缺乏随机对照的高级别证据。
- 纳入研究数仅9项、患者406例,样本量有限。
- 研究间异质性及汇总分析方法可能影响结果稳健性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of carbon ion radiation therapy (CIRT) in treating locally advanced pancreatic cancer (LAPC) lacks high-level medical evidence. This study aimed to assess the efficacy and safety of CIRT for LAPC through a pooled analysis of single-arm studies. METHODS AND MATERIALS: Prospective or retrospective clinical studies of CIRT for LAPC with or without chemotherapy before, concurrent, and/or after CIRT were included in the analysis. A systematic search of the Embase, PubMed, and Cochrane Library databases was conducted for studies until September, 2025. These articles were independently screened, and data were extracted by 2 researchers. Statistical analysis of outcomes was performed using STATA 15.1. RESULTS: A total of 522 related articles were retrieved, and 9 single-arm studies with a total of 406 patients with LAPC were included. The pooled local control (LC) rates at 1 and 2 years were 84% and 64%, respectively, with higher prescribed doses showing improved LC compared with lower doses (89% vs 69% at 1 year; 72% vs 30% at 2 years). The overall survival rates at 1 and 2 years were 65% and 38%, respectively. A clear survival benefit of CIRT was observed in studies with concurrent chemotherapy than without (73% vs 53% at 1 year; 44% vs 22% at 2 years). Prior chemotherapy administration reduced the incidence of distant metastases (69% vs 85%). Regarding toxicities above G3, the pooled incidences of nonhematological toxicity and hematological toxicity were 8% and 24%, respectively. CONCLUSIONS: Encouraging LC and overall survival outcomes were observed in this pooled analysis of CIRT as a plausible treatment strategy for LAPC. Subgroup analyses suggested that higher doses, concurrent chemotherapy, and prior chemotherapy may further enhance the efficacy. Meanwhile, CIRT has acceptable toxicities even when it is administered concurrently with chemotherapy.
引用
- Liu S, Hu X, Tong R, et al. Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of Single-arm Studies. Int J Radiat Oncol Biol Phys. 2026. PMID: 41839377. doi:10.1016/j.ijrobp.2026.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。